

# **EXHIBIT A**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	6
-------	---	----	---

**Complete if Known**

Application Number	10/621,027
Filing Date	July 16, 2003
First Named Inventor	CHEUNG, Nai-Kong V.
Art Unit	1623
Examiner Name	Eric Olson
Attorney Docket Number	639-B-PCT-US

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> Number <sup>3</sup> Kind Code <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
	16	WO 2007084661	07-26-2007	Sloan-Kettering Institute for Cancer Research	
	17	WO 2006085895	08-17-2006	Biopolymer Engineering Inc et al.	
	18	WO 2005049044	06-02-2005	Laboratoires Goemar SA	
	19	WO 2004030613	04-15-2004	University of Louisville Research Foundation, Inc.	
	20	WO 02058711	08-01-2002	Sloan-Kettering Institute for Cancer Research	
	21	WO 2006119395	11-09-2006	Biopolymer Engineering	

Examiner Signature	Date Considered
-----------------------	--------------------

**\*EXAMINER:** Initial if reference conforms, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and note reason. <sup>1</sup> Provide a copy of the form with two attachments: <sup>2</sup> Applicant's citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Applicant that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the *inventor* of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

**Transmittal and instructions:** This form and accompanying instructions are required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to a life and by the USPTO to complete an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2

of	6
----	---

**Complete if Known**

Application Number	10/621,027
Filing Date	July 16, 2003
First Named Inventor	CHEUNG, Nai-Kong V.
Art Unit	1623
Examiner Name	Eric Olson
Attorney Docket Number	639-B-PCT-US

## U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code <sup>2</sup> -Number <sup>3</sup> -Kind Code <sup>4</sup> (if known)			
	22	WO 0180807	11-01-2001	Goemar Lab SA	
	23	WO 2005027938	03-31-2005	Goemar Lab SA	
	24	WO 03004507	01-16-2003	Research Center for Eco-Environmental Sciences	
	25	WO 0168105	09-20-2001	Sealed Corporation Cardio Research Projects & Research Ltd. Limited	
	26	WO 2005027936	03-31-2005	Laboratoires Goemar SA	
	27	EP0194851	09-17-1986	The Wistar Institute	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/621,027
Filing Date	July 16, 2003
First Named Inventor	CHEUNG, Nai-Kong V.
Art Unit	1623
Examiner Name	Eric Olson
Attorney Docket Number	639-B-PCT-US

Sheet 3 of 6

**OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	4	U.S. Publication No. US-2006-0020128, January 26, 2006, Nai-Kong CHEUNG, "Therapy-Enhancing Glucan."	
	5	U.S. Publication No. US-2006-0188506, August 24, 2006, Nai-Kong CHEUNG, "Therapy-Enhancing Glucan."	
	6	U.S. Publication No. US-2007-0059310, March 15, 2007, Steven KAREL, "Therapeutic combination compositions and methods of using same."	
	7	U.S. Publication No. US-2006-0165700, July 27, 2006, OSTROFF et al., "Cancer therapy using whole glucan particles and antibodies."	
	8	U.S. Publication No. US-2005-0118187, June 2, 2005, Baofa YU, "Combinations and methods for treating neoplasms."	
	9	U.S. Publication No. US-2007-0134259, June 14, 2007, BUNDLE et al., "Methods and compositions for pharmacologically controlled targeted immunotherapy."	
	10	U.S. Publication No. US-2007-0020232, January 25, 2007, ROSSIGNOL et al., "Compositions and methods for cancer immunotherapy."	
	11	U.S. Publication No. US-2006-0009419, January 12, 2006, Gordon D. ROSS, "Cancer Therapy using beta glucan and antibodies."	
	12	U.S. Publication No. US-2005-0208079, September 22, 2005, CASSONE et al., "Glucan-based vaccines."	
	13	U.S. Publication No. US-2002-0044919, April 18, 2002, Baofa YU, "Combinations and methods for treating neoplasms."	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

6

**Complete if Known**

Application Number	10/621,027
Filing Date	July 16, 2003
First Named Inventor	CHEUNG, Nai-Kong V.
Art Unit	1623
Examiner Name	Eric Olson
Attorney Docket Number	639-B-PCT-US

**OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	14	U.S. Publication No. US-2006-0263355, November 23, 2006, QUAN et al., "Treatment of bone disorders."	
	15	U.S. Publication No. US-2002-0119928, August 29, 2002, MCANALLEY et al., "Dietary supplement compositions."	
	28	ADACHI et al., 1990, "Macrophage Activation in Vitro by Chemically Cross-Linked (1-3)- $\beta$ -D-Glucans", Chem. Pharm. Bull., 38(4):988-992.	
	29	AZUMA, Ichiro, "Development of Immunostimulants in Japan", Immunostimulants: Now and Tomorrow, 41-56.	
	30	BLUHM et al., 1977, "The triple helical structure of lentinan, a linear $\beta$ -(1 $\rightarrow$ 3)-D-glucan", Can J Chem, 55:293-299.	
	31	BOGWALD et al., 1982, "The Cytotoxic Effect of Mouse Macrophages Stimulated in Vitro by a $\beta$ -1,3-D-Glucan from Yeast Cell Walls", Scandinavian Journal of Immunology, 15:297-304.	
	32	CHIHARA et al., 1982, "Current Status and Perspectives of Immunomodulators of Microbial Origin", International Journal of Tissue Reactions, 4:207-226.	
	33	MAEDA et al., 1971, "Lentinan, a new immune-accelerator of cell-mediated responses", Nature, 229:634.	
	34	CHIHARA et al., 1970, "Fractionation and purification of the polysaccharides with Marked Antitumor Activity, Especially Lentinan, from Lentinus edodes (Berk.) Sing. (an Edible Mushroom)", Cancer Res, 30:2778-2781.	
	35	CHIHARA et al., 1981, "The antitumor polysaccharide Lentinan: an overview", Manipulation of Host Defence Mechanisms, 1-16.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 422 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

<b>Application Number</b>	10/621,027
<b>Filing Date</b>	July 16, 2003
<b>First Named Inventor</b>	CHEUNG, Nai-Kong V.
<b>Art Unit</b>	1623
<b>Examiner Name</b>	Eric Olson
<b>Attorney Docket Number</b>	639-B-PT-US

Sheet 5 of 6

**OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	36	CHIHARA et al., 1987 "Antitumor and Metastasis-Inhibitory Activities of Lentinan as an Immunomodulator: An Overview", Cancer Detect. Prev. Suppl. 1:423-443.(	
	37	DI LUZIO et al., 1985, "Glucans as Immunomodulators", Advances in Immunopharmacology, Pergamon Press, NY, 369-375	
	38	DI LUZIO et al., 1980, "Comparative Evaluation of the Tumor Inhibitory and Antibacterial Activity of Solubilized and Particulate Glucan", Recent Results in Cancer Research, 75:165-172.	
	39	DI LUZIO, Nicholas R., 1985, "Update on the Immunomodulating Activities of Glucans", Springer Seminars in Immunopathology, 8:387-400.	
	40	HAMURO et al., 1971, "The significance of the higher structure of the polysaccharides lentinan and pachymaran with regard to their antitumor activity", Chem. Biol. Interactions, 3:69-71.	
	41	HAMURO et al., 1978, "Solid phase activation of alternative pathway of complement by $\beta$ -1,3-glucans and its possible role for tumour regressing activity", Immunology, 34:695-705.	
	42	JAMAS et al., 1990, "Spectral Analysis of Glucan Produced by Wild-Type and Mutant Saccharomyces cerevisiae", Carbohydrate Polymers, 13:207-219.	
	43	PATCHEN et al., 1984, "Soluble Polyglycans Enhance Recovery from Cobalt-60-Induced Hemopoietic Injury", Journal of Biological Response Modifiers, 3:627-633.	
	44	SAITO et al., 1977, "A C-N.M.R.-spectral study of a gel forming, branched (1 $\rightarrow$ 3)- $\beta$ -D-Glucan, (Lentinan) from Lentinus edodes, and its acid-degraded fractions. Structure, and Dependence of Confirmation on the Molecular Weight", Carbohydrate Research, 58:293-305.	
	45	SASAKI et al., 1976, "Antitumor Activity of Degraded Products of Lentinan: it's Correlation with Molecular Weight", Gann, 67:191-195.	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete If Known**

Application Number	10/621,027
Filing Date	July 16, 2003
First Named Inventor	CHEUNG, Nai-Kong V.
Art Unit	1623
Examiner Name	Eric Olson
Attorney Docket Number	639-B-PCT-US

Sheet 6 of 6

**OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	46	SELJELID et al., 1977, "Glycan Stimulation of Macrophages in Vitro", Experimental Cell Research, 131:121-129.	
	47	SINGH et al., 1974, "Scleroglucan, an antitumor polysaccharide from Sclerotium glaucum", Carbohydrate Research, 37:245-247.	
	48	SUZUKI et al., 1989, "Immunomodulation by Orally Administered $\beta$ -Glucan in Mice", International Journal of Immunopharmacology, 11:761-769.	
	49	KIRBY et al., 1981, "Oat-bran intake selectively lowers serum low-density lipoprotein cholesterol concentrations of hypercholesterolemic men", American Journal of Clinical Nutrition, 34:824-829.	
	50	PEAT et al., 1958, "Polysaccharides of Baker's Yeast. Part II. Yeast Glucan", Journal Chem. Soc. Part 1, 3862-3868.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 36 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.